Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?

Area of Science:

• Pediatric Pulmonology
• Neonatal Respiratory Medicine
• Pharmacology

Background:

• Inhaled nitric oxide (INO) is FDA-approved solely for neonates ( > 34 weeks gestation) experiencing hypoxic respiratory failure-associated pulmonary hypertension.
• Off-label INO use is prevalent in pediatric patients, lacking robust evidence for survival benefits, prompting re-evaluation for use beyond the neonatal period.
• Rising healthcare costs and limited evidence have led to the adoption of inhaled prostacyclin as a less expensive alternative to INO, introducing distinct patient safety considerations.

Purpose of the Study:

• To review the current evidence on inhaled pulmonary vasodilators in pediatric patients.
• To assess patient safety considerations associated with inhaled pulmonary vasodilators in the pediatric population.

Main Methods:

• Literature review of current evidence.
• Analysis of patient safety data.
• Evaluation of inhaled pulmonary vasodilators.

Main Results:

• Evidence for survival benefit of off-label INO use in pediatrics is limited.
• Inhaled prostacyclin presents unique patient safety concerns.
• Current data is insufficient to guide optimal use of inhaled pulmonary vasodilators in children.

Conclusions:

• Further research is needed to establish efficacy and safety of inhaled pulmonary vasodilators in pediatric populations.
• Clinical guidelines are necessary to direct the appropriate use of inhaled nitric oxide and inhaled prostacyclin in children.
• Balancing cost-effectiveness with patient safety is crucial when selecting inhaled pulmonary vasodilators for pediatric use.